PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23613396-3	2013	The purpose of this study was to investigate the predictive value of the presence of K-RAS and B-RAF mutations on the outcome of patients with mCRC treated with FOLFIRI and bevacizumab combination therapy.	FOLFIRI regimen	161-168	KRAS proto-oncogene, GTPase	Homo sapiens	85-90	
23613396-3	2013	The purpose of this study was to investigate the predictive value of the presence of K-RAS and B-RAF mutations on the outcome of patients with mCRC treated with FOLFIRI and bevacizumab combination therapy.	FOLFIRI regimen	161-168	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	95-100